Enliven Therapeutics Inc. (ELVN)

Sep 21, 2026

Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently exercised stock options for 3,982 shares at $14.85 per share and subsequently sold 6,018 shares in three separate transactions on September 17, 2026. These transactions, executed under a Rule 10b5-1 trading plan adopted in March 2026, resulted in weighted average sales prices ranging from $50.0286 to $51.4929. Following these activities, Hohl directly holds 38,000 shares and retains options for 181,018 shares.

Sep 21, 2026

Enliven Therapeutics' CFO, Benjamin Hohl, sold 6,018 shares of the company (ELVN) on September 17, 2026, for a total of $303,003. This transaction was disclosed in a recent SEC filing. Access to the full details of this report requires a premium subscription.

Sep 18, 2026

Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer, with two programs in Phase 1 trials targeting chronic myeloid leukemia and non-small cell lung cancer. Despite lacking current revenue, the company holds a market cap of $3.68 billion and is seen as a significant growth opportunity by analysts, who project an average 47.09% upside potential. Investors are advised to monitor clinical trial progress and regulatory milestones for future stock performance.